Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 13/20 | 0.61 |
| ▸ | CA2 | P00918 | 13/20 | 0.61 |
| ▸ | CA12 | O43570 | 7/20 | 0.61 |
| ▸ | CA9 | Q16790 | 7/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | CCNC | P24863 | 1/20 | 0.45 |
| ▸ | CDK8 | P49336 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29040473 | 1.00 | CA1 (0.61) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL29040417 | 1.00 | CA1 (0.61) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL29040410 | 1.00 | CA1 (0.61) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL4640090 | 1.00 | CA1 (0.61) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL16930099 | 1.00 | CA1 (0.61) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL23835564 | 1.00 | CA1 (0.61) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL2822013 | 0.99 | CA1 (0.60) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL487585 | 0.95 | CA1 (0.59) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL17162051 | 0.94 | CA1 (0.55) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL22326309 | 0.92 | CA1 (0.56) | CA1CA2CA12CA9TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250345446-A1 | BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES | DRAUPNIR BIO APS (DK) | 2025-11-13 | — | — | US | disclosed |
| EP-4543858-A1 | BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES | Draupnir Bio ApS (DK) | 2025-04-30 | — | — | EP | disclosed |
| US-20250074904-A1 | NSD2-TARGETED CHECMICAL DEGRADERTS AND COMPOSITIONS AND METHODS OF USE THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2025-03-06 | — | — | US | disclosed |
| WO-2023247754-A1 | BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES | DRAUPNIR BIO APS (DK) | 2023-12-28 | — | — | WO | disclosed |
| US-20230242506-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | GENENTECHT, INC. (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230167105-A1 | BCL-2 PROTEIN INHIBITORS | RECURIUM IP HOLDINGS, LLC | 2023-06-01 | — | — | US | disclosed |
| WO-2023091565-A1 | NSD2-TARGETED CHEMICAL DEGRADERS AND COMPOSITIONS AND METHODS OF USE THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2023-05-25 | — | — | WO | disclosed |
| WO-2023091565-A1 | NSD2-TARGETED CHEMICAL DEGRADERS AND COMPOSITIONS AND METHODS OF USE THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2023-05-25 | — | — | WO | disclosed |
| EP-4107152-A1 | BCL-2 PROTEIN INHIBITORS | Recurium IP Holdings, LLC (US) | 2022-12-28 | — | — | EP | disclosed |
| US-20220105188-A1 | TARGET PROTEIN EED DEGRADATION-INDUCING DEGRADUCER, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATED TO EED, EZH2, OR PRC2, COMPRISING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2022-04-07 | — | — | US | disclosed |
| US-20120301894-A1 | LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS | Life Technologies Corporation (US) | 2012-11-29 | — | — | US | disclosed |
| US-8114636-B2 | Labeling and detection of nucleic acids | Life Technologies Corporation (US) | 2012-02-14 | — | — | US | disclosed |
| US-8114636-B2 | Labeling and detection of nucleic acids | Life Technologies Corporation (US) | 2012-02-14 | — | — | US | disclosed |
| US-20100261181-A1 | LABELING AND DETECTION OF NUCLEIC ACIDS | Life Technologies Corporation (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100261181-A1 | LABELING AND DETECTION OF NUCLEIC ACIDS | Life Technologies Corporation (US) | 2010-10-14 | — | — | US | disclosed |
| US-20080050731-A1 | LABELING AND DETECTION OF NUCLEIC ACIDS | INVITROGEN CORPORATION (US) | 2008-02-28 | — | — | US | disclosed |
| US-20080050731-A1 | LABELING AND DETECTION OF NUCLEIC ACIDS | INVITROGEN CORPORATION (US) | 2008-02-28 | — | — | US | disclosed |
| US-20070249014-A1 | LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS | INVITROGEN CORPORATION (US) | 2007-10-25 | — | — | US | disclosed |
| WO-2007082897-A2 | POLYSACCHARIDE-CYCLODEXTRIN CONJUGATES | B. BRAUN MELSUNGEN AG (DE) | 2007-07-26 | — | — | WO | disclosed |
| EP-1808181-A1 | Polysaccharide-cyclodextrin conjugates | B. BRAUN MELSUNGEN AG (DE) | 2007-07-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220105188-A1 | TARGET PROTEIN EED DEGRADATION-INDUCING DEGRADUCER, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATED TO EED, EZH2, OR PRC2, COMPRISING SAME AS ACTIVE INGREDIENT | EED, VHL, CUL1 | CA1 2108/4885CA2 3802/4885CA12 3934/4885 |
| US-20250345446-A1 | BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES | SORT1, SCARB1, LAMP1 | CA1 4441/4885CA2 4158/4885CA12 4066/4885 |
| US-20250074904-A1 | NSD2-TARGETED CHECMICAL DEGRADERTS AND COMPOSITIONS AND METHODS OF USE THEREOF | NCOR2, NSD2, NCOR1 | CA1 4590/4885CA2 4561/4885CA12 4129/4885 |
| US-20230242506-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | TEAD1, TEAD2, TEAD4 | CA1 4225/4885CA2 1815/4885CA12 3879/4885 |
| US-20230167105-A1 | BCL-2 PROTEIN INHIBITORS | BCL2, BCL2L1, BCL2L2 | CA1 2883/4885CA2 1299/4885CA12 3384/4885 |
| US-20070249014-A1 | LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS | PTMS, DNPEP, BTD | CA1 969/4885CA2 2515/4885CA12 801/4885 |
| US-20100261181-A1 | LABELING AND DETECTION OF NUCLEIC ACIDS | RNGTT, ADAR, ALKBH1 | CA1 998/4885CA2 1593/4885CA12 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.